Von Maksym Misichenko · Yahoo Finance ·
Was KI-Agenten über diese Nachricht denken
The panelists agree that Eli Lilly's Verve-102 and retatrutide programs show early promise but face significant hurdles, including manufacturing challenges, regulatory risks, and payer acceptance. The market's high valuation already prices in perfection, making it vulnerable to any setbacks.
Risiko: Regulatory tail risk and payer acceptance for one-time edits
Chance: Potential paradigm shift from chronic GLP-1 injections to one-and-done genetic medicine
Diese Analyse wird vom StockScreener-Pipeline generiert — vier führende LLM (Claude, GPT, Gemini, Grok) erhalten identische Prompts mit integrierten Anti-Halluzinations-Schutzvorrichtungen. Methodik lesen →
Eli Lilly and Company (NYSE:LLY) is one of the
12 Most Profitable Stocks to Invest In.
Am 25. Mai 2026 gab Eli Lilly and Company (NYSE:LLY) positive Phase 1b Heart-2 Studienergebnisse für Verve-102 bekannt, ein investigatives in vivo Base-Editing-Medikament, das entwickelt wurde, um dauerhaft das PCSK9-Gen in der Leber auszuschalten und den niedrigdichtigen Lipoprotein-Cholesterinspiegel nach einer einzigen Infusion zu senken. In einer Zwischenanalyse von 35 Teilnehmern produzierte eine Dosis von Verve-102 dosisabhängige mittlere PCSK9-Reduktionen im Bereich von 51 % bis 88 %, von der 0,3 mg/kg-Dosis bis zur 1,0 mg/kg-Dosis. Die entsprechenden mittleren LDL-C-Reduktionen betrugen 9 %, 44 %, 45 %, 33 %, 51 % und 62 %, wobei eine Haltbarkeit bis zu 18 Monate nach der Behandlung beobachtet wurde.
Am 21. Mai 2026 sagte Wolfe Research, dass Eli Lilly and Company (NYSE:LLY) bahnbrechende Phase-3-Ergebnisse für Retatrutid gemeldet hat, die einen „führenden“ Gewichtsverlust von bis zu 26,1 % nach 80 Wochen und über 30 % nach 104 Wochen bei Teilnehmern mit höherem BMI zeigten. Wolfe sagte, dass die Daten auch breite Verbesserungen bei wichtigen kardiovaskulären Risikomarkern zeigten, was Eli Lillys GLP-1-Franchise-Führerschaft und das therapeutische Profil für Adipositas weiter stärkt. Wolfe beließ eine Outperform-Bewertung und ein Kursziel von 1.350 US-Dollar für die Aktien.
Unterdessen beließ RBC Capital eine Outperform-Bewertung und ein Kursziel von 1.250 US-Dollar für Eli Lilly and Company (NYSE:LLY). RBC sagte, die Phase-3-Versuch mit Retatrutid sei ein klarer Erfolg, der durch ein sauberes Sicherheitsprofil und eine branchenführende Wirksamkeit bei allen Dosen gekennzeichnet sei. RBC sagte, es rechne mit einer Markteinführung von Retatrutid im Jahr 2027, einem Umsatz von 4,9 Milliarden US-Dollar im Jahr 2030 und einem Umsatz von 11,0 Milliarden US-Dollar im Jahr 2034 mit einer Wahrscheinlichkeit von 70 % für den Erfolg.
Eli Lilly and Company (NYSE:LLY) entdeckt, entwickelt, produziert und vermarktet international humanpharmazeutische Produkte.
Obwohl wir das Potenzial von LLY als Investition anerkennen, glauben wir, dass bestimmte AI-Aktien ein größeres Aufwärtspotenzial bieten und ein geringeres Abwärtsrisiko aufweisen. Wenn Sie nach einer äußerst unterbewerteten AI-Aktie suchen, die auch erheblich von Trump-Ära-Zöllen und dem Trend zur Verlagerung der Produktion profitieren kann, sehen Sie sich unseren kostenlosen Bericht über die besten kurzfristigen AI-Aktien an.
WEITER LESEN: 33 Aktien, die sich in 3 Jahren verdoppeln sollten und Cathie Wood 2026 Portfolio: 10 beste Aktien zum Kaufen.** **
Disclosure: Keine. Folgen Sie Insider Monkey auf Google News.
Vier führende AI-Modelle diskutieren diesen Artikel
"Early-stage gene-editing data and retatrutide results are encouraging but remain too preliminary to override pipeline and competitive risks."
The article spotlights early positive data for Verve-102 (51-88% PCSK9 reduction, up to 62% LDL-C drop) and retatrutide Phase 3 weight loss up to 26.1%, plus analyst targets of $1,250-$1,350. These support LLY's cardiometabolic pipeline strength, yet the piece is framed within a promotional push for unrelated AI stocks, and dates reference 2026 events. Phase 1b results involve only 35 participants with variable durability, while retatrutide modeling assumes 70% success and 2027 launch. Missing context includes base-editing safety risks, obesity market competition, and how in vivo gene editing scales commercially versus existing GLP-1 therapies.
The strongest case against a neutral stance is that dose-dependent, durable LDL-C reductions in humans could de-risk the platform faster than expected, justifying premium multiples if retatrutide hits modeled $11B sales by 2034.
"Verve-102's PCSK9 knockdown doesn't proportionally reduce LDL-C, raising questions about mechanism and real-world efficacy before Phase 2 data; retatrutide upside is real but already priced in at current multiples."
Verve-102's Phase 1b data is genuinely impressive on the surface—88% PCSK9 reduction at top dose, 18-month durability—but the LDL-C response is oddly flat: only 62% reduction despite 88% target suppression. This disconnect suggests either target engagement doesn't linearly drive efficacy, or there's compensatory biology we don't yet understand. The retatrutide Phase 3 wins are real, but RBC's $11B 2034 sales forecast assumes zero competition erosion in a crowded GLP-1 market by then. More critically: both programs are years from peak revenue, and LLY's current valuation already prices in obesity dominance. The article's pivot to 'AI stocks offer greater upside' is editorial noise, but it flags real opportunity cost.
If Verve-102's PCSK9 suppression translates to durable cardiovascular outcomes in Phase 2b/3, a one-time genetic edit could disrupt the entire statin and PCSK9 inhibitor market—potentially $50B+ TAM—making current LLY valuation cheap on a 10-year view.
"Lilly is transitioning from a traditional pharmaceutical company to a platform-based biotech powerhouse capable of dominating both the obesity market and the next generation of genetic cardiovascular medicine."
Eli Lilly is effectively building a 'cardiometabolic fortress.' The Verve-102 data, while early-stage, represents a paradigm shift from chronic GLP-1 injections to potentially one-and-done genetic medicine, which would fundamentally disrupt the long-term revenue model for chronic care. When combined with the 26-30% weight loss efficacy of retatrutide, Lilly is positioning itself to capture both the lifestyle and the underlying genetic drivers of cardiovascular disease. However, the market is currently pricing in perfection. With a forward P/E ratio exceeding 60x, any regulatory hiccup in the 2027 retatrutide launch or unforeseen long-term safety signals from gene editing will lead to a violent de-rating of the stock.
The immense cost and clinical complexity of in vivo gene editing may limit Verve-102 to a niche, ultra-high-risk patient population, failing to achieve the mass-market scale required to justify Lilly's current premium valuation.
"Verve-102’s early data are not a reliable foundation for near-term upside given unresolved safety/regulatory risks and lack of clinical outcome proof."
Verve-102 Phase 1b data show intriguing, but very early signals: N=35, dose-responsive PCSK9 reductions (51–88%) and LDL-C drops up to ~62% with durability claimed to 18 months. Yet safety data are absent, delivery/remedy specifics unclear, and in vivo base editing carries significant off-target and immune risk, plus an uncertain regulatory path for a permanent liver edit. Translation from LDL-C reduction to reduced ASCVD events is not demonstrated. The obesity program (retatrutide) also remains early-stage; even with strong signals, long-run safety, cost, and payer dynamics will drive real upside. The stock’s rally could be fragile if these risks materialize or if timelines slip.
The strongest counter: Phase 1b size and scope are too small to infer durable clinical benefit; safety/off-target risks and a murky regulatory path could derail Verve-102 before Phase 2/3 even starts, making upside speculative.
"Verve-102's manufacturing and reimbursement hurdles are understated relative to retatrutide's scalable peptide production."
Gemini assumes Verve-102 scales like retatrutide into a broad cardiometabolic fortress, yet in vivo base editing demands specialized GMP manufacturing of LNPs with lot-to-lot editing consistency that Lilly has never demonstrated at obesity-drug volumes. This bottleneck, plus one-time therapy reimbursement fights with payers, could confine Verve-102 to narrow high-risk segments even if durability holds, capping revenue well below the $50B TAM cited elsewhere and amplifying de-rating risk if timelines slip.
"Manufacturing scale is achievable; the real gate is whether payers value one-time durability over chronic therapy economics."
Grok's manufacturing bottleneck argument is sharp, but it conflates two separate problems. LNP consistency is solvable—Moderna and BioNTech scaled it to billions of doses. The real constraint is payer reimbursement for one-time edits in a $100K+ range competing against $300/month GLP-1s. That's a willingness-to-pay problem, not a GMP problem. If Verve-102 shows durable CV outcomes, payers may accept it; if not, manufacturing capacity becomes irrelevant.
"The permanent nature of in vivo base editing creates a regulatory and safety barrier that prevents it from scaling like transient mRNA therapies."
Claude, your LNP manufacturing comparison is dangerous. Moderna's mRNA degrades; it doesn't permanently alter the genome. The regulatory and safety burden of delivering a CRISPR-based base editor—which carries permanent off-target risk—is orders of magnitude higher than a transient vaccine. Scaling this isn't just a volume issue; it's a massive clinical trial hurdle. If the FDA requires long-term monitoring for oncogenic risk, the 'one-and-done' cost-benefit analysis against GLP-1s collapses entirely, regardless of payer willingness.
"Long-term safety tail risk and payer/regulatory hurdles for permanent genome edits could cap Verve-102's upside even if CV outcomes look durable."
Gemini's one-and-done thesis hinges on favorable CV outcomes and payer acceptance, but permanent liver base editing carries a long-tail safety burden regulators will scrutinize for decades. Even with durable LDL-C/ASCVD signals, long-term oncogenic and off-target risks could trigger post-approval surveillance costs, denial of coverage, and slower uptake than implied. Manufacturing isn't the only bottleneck—the regulatory tail risk and payer risk could erode the multiple from a 50B TAM to a fraction of that.
The panelists agree that Eli Lilly's Verve-102 and retatrutide programs show early promise but face significant hurdles, including manufacturing challenges, regulatory risks, and payer acceptance. The market's high valuation already prices in perfection, making it vulnerable to any setbacks.
Potential paradigm shift from chronic GLP-1 injections to one-and-done genetic medicine
Regulatory tail risk and payer acceptance for one-time edits